{"transactions":[{"id":805100,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":55200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":55200,"derivative":{"exercise_price":1.33,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":55200},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805099,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":55200},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805098,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.33,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805097,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805096,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":1.33,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":805095,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:50.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\") or the Issuer's 2022 Inducement Plan, as amended (the \"2022 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.18,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001746473-26-000055","document":"wk-form4_1776458567.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000055/wk-form4_1776458567.xml","form_type":"4"}},{"id":930967,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T21:36:47.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":300000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001746473-26-000019","document":"wk-form4_1769463404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000019/wk-form4_1769463404.xml","form_type":"4"}},{"id":933134,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":52031,"kind":"person","name":"Kuo Minnie","position":1,"cik":"0002101360","reported_name":"Kuo Minnie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-23T02:38:28.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":6917,"price":1.28,"value":8853.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":37806,"source":{"system":"sec-edgar","filing":"0001746473-26-000008","document":"wk-form4_1769135906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000008/wk-form4_1769135906.xml","form_type":"4"}}]}